Welcome to the e-CCO Library!

P501: Safety of peri-operative biologics in patients with IBD undergoing resective bowel surgery: experiences of a single center cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ochsenkuehn, T.(1)*;Tillack-Schreiber, C.(2);Bader, F.(3);Maximilian, S.(3);Szokodi, D.(4);Tomelden, J.(5);Waggershauser, C.(6);Braun, I.(4);Schnitzler, F.(7);
Created: Friday, 14 July 2023, 11:05 AM
P501: Vedolizumab for UC after infliximab failure in PSC patients after OLTx: Two case reports
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Drastich*, J. Brezina, L. Bajer, M. Benes, J. Spicak

Created: Thursday, 21 February 2019, 9:14 AM
P501: Vedolizumab is associated with longer drug sustainability compared to infliximab in moderate-to-severe Ulcerative Colitis: a real-world cohort study
Year: 2022
Source: ECCO'22
Authors: Konikoff, T.(1);Yanai, H.(1);Banai, H.(1);Avni-Biron, I.(1);Snir, Y.(1);Broitman, L.(1);Barkan, R.(1);Checholin, L.(1);Dotan, I.(1);Ollech, J.(2);
Created: Friday, 11 February 2022, 3:56 PM
P502 Tumour necrosis factor antagonists are superior to anti-integrin and anti-IL-12/23 therapies for preventing postoperative recurrence in adult Crohn’s disease patients requiring postoperative therapy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Nakamura1, R. Shah2, M. Sachs3, S. Chang4, D. Hudesman4, B. Click5, J. Axelrad4

Created: Thursday, 30 January 2020, 10:12 AM
P502: Application of an algorithm-based precision-dosing model to a real-world cohort of patients on infliximab maintenance therapy: implications for drug usage and cost
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nguyen, A.(1,2,3)*;Gibson, P.(1,2);Upton , R.(4,5);Mould, D.(4);Sparrow, M.P.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P502: Clinical and endoscopic features of secondary loss of response cases in patients with Crohn’s disease treated with infliximab by top-down strategy: A case–control study
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Miyazaki1*, A. Fujimori1, R. Koshiba1, K. Fujimoto1, T. Sato1, M. Kawai2, Y. Kita1, K. Kamikozuru1, T. Takagawa2, Y. Yokoyama1, N. Hida1, K. Watanabe2, S. Nakamura1

Created: Thursday, 21 February 2019, 9:14 AM
P502: Correlation between soluble suppression of tumorigenicity 2 (sST2) and endoscopic activity in patients with moderate to severe ulcerative colitis under golimumab treatment: results of the EVOLUTION study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. Magro*1,2, S. Lopes1, M. Silva1, R. Coelho1, F. Portela3, D. Branquinho3, L. Correia4, S. Fernandes4, M. Cravo5, P. Caldeira6, H. Sousa6,7, M. Patita8, P. Lago9, J. Ramos10, J. Afonso2, I. Redondo11, P. Machado11, G. Philip12, J. Lopes2, F. Carneiro2,13

Created: Friday, 22 February 2019, 9:41 AM
P502: Dietary habits and nutritional status in children and adolescents with Inflammatory Bowel Disease: an italian multicenter case-control study (NUTRIBD study)
Year: 2021
Source: ECCO'21 Virtual
Authors: Gatti, S.(1);Vallorani, M.(1);zoppi, E.(1);aloi, M.(2);bramuzzo, M.(3);felici, E.(4);panceri, R.(5);ciacchini, B.(6);catassi, G.(2);grazian, F.(3);catassi, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P502: Different presentation of tuberculosis associated with anti-TNF therapy among patients with Inflammatory Bowel Disease in endemic area: observation from China
Year: 2022
Source: ECCO'22
Authors: Ye, L.(1,2);Wu, L.(3);Tang, J.(4);Mao, R.(5);Cao, Q.(3);
Created: Friday, 11 February 2022, 3:56 PM
P502: Persistence of remission amongst patients with inflammatory bowel disease after adalimumab therapy is stopped: economic and clinical implications
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

x. Cortés*1, J. R. MOLÉS2, S. Fernández3, J. Clofent3, M. Moreno4, J. Rodriguez3, J. Primo3

Created: Friday, 22 February 2019, 9:49 AM
P502: Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Zezos P.*1, Kabakchiev B.2, Weizman A.V.1, Nguyen G.C.1, Narula N.1, Croitoru K.1, Steinhart A.H.1, Silverberg M.S.1

Created: Wednesday, 20 February 2019, 10:36 AM
P503 Changes in clinical use of vedolizumab are driven by lower drug costs and are associated with better outcomes: a real-life single-centre Spanish experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. Gonzalez Lama, M. Calvo, V. Matallana, I. Gonzalez-Partida, I. Omella, M.I. Vera

Created: Thursday, 30 January 2020, 10:12 AM
P503: Can daily SCCAI measurements over a 6-month period better phenotype the pattern of disease in ulcerative colitis?
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Walsh1*, A. Kormilitzin2, C. Hinds3, V. Sexton4, J. Wilson1, M. Peters5, O. Brain1, S. Keshav1, H. Uhlig1, J. Geddes4, G. Goodwin4, G. Collins6, S. Travis1

Created: Thursday, 21 February 2019, 9:14 AM
P503: Early TNF-antagonist maintenance therapy results in better outcomes than immunomodulators in paediatric Crohn's disease: A multi-centre prospective cohort study
Year: 2022
Source: ECCO'22
Authors: Schneider, R.(1,2);Jacobson, K.(3);Huynh, H.(4);Mack, D.(5);Deslandres, C.(6);deBruyn, J.(7);El-Matary, W.(8);Otley, A.(9);Lawrence, S.(3);Wine, E.(4);Sherlock, M.(10);Critch, J.(11);Jantchou, P.(6);Rashid, M.(9);Carroll, M.(4);Bax, K.(12);Seidman, E.(13);Benchimol, E.(1,2);Ricciuto, A.(1,2);Wu, A.(1);Pullenayegum, E.(2);Walters, T.(1);Nguyen, G.(2);Griffiths, A.(1,2);Church, P.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P503: Inflammatory bowel disease video-consulting: a satisfaction survey during the second wave of Covid-19 pandemics
Year: 2021
Source: ECCO'21 Virtual
Authors: Todeschini, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P503: Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ametzazurra A.1, Rivera N.2, Hernández A.M.1, Arreba M.P.3, Ruiz E.4, Ortíz J.3, Muñoz M.d.C.3, Torres N.1, Pascual J.1, Martínez A.1, Allande M.J.2, Nagore D.*1

Created: Wednesday, 20 February 2019, 10:36 AM
P503: Tacrolimus vs anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Yamamoto*, T. Shimoyama, S. Umegae, K. Matsumoto

Created: Friday, 22 February 2019, 9:49 AM
P503: The risk of mild, moderate and severe infections in IBD patients: results from a prospective, multicentre, observational cohort study – PRIQ
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Rezazadeh Ardabili, A.(1,2)*;van Esser, D.(1);Wintjens, D.(1);Cilissen, M.(1);Deben, D.(3);Mujagic, Z.(1,2);Russ, F.(4);Stassen, L.(2,5);van Bodegraven, A.(4);Wong, D.(3);Winkens, B.(6);Jonkers, D.(1,2);Romberg-Camps, M.(4);Pierik, M.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P503: Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Biemans*1, J. van der Woude2, G. Dijkstra3, A. van der Meulen-de Jong4, B. Oldenburg5, N. de Boer6, M. Löwenberg7, N. Srivastava8, J. Jansen9, R. West10, A. de Vries2, J. Haans11, M. Pierik11, F. Hoentjen12

Created: Friday, 22 February 2019, 9:41 AM
P504 Remote cannabis-therapy management platform for IBD patients: performance assessment
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Sweed1, C. Shapira2, T. Naftali3

Created: Thursday, 30 January 2020, 10:12 AM